Dr. Steven Theriault reports

CYTOPHAGE LAUNCHES READY-TO-USE LYOPHILIZED PHAGE TABLETS TO IMPROVE GUT HEALTH IN POULTRY

Cytophage Technologies Ltd. has launched a simplified application option for bacteriophages that can treat multiple types of bacteria, such as E. coli and salmonella, throughout the life cycle of a chicken. The lyophilized tablets were first developed and tested in the spring of 2024 and are now being targeted for wider application.

The lyophilized phage tablets are designed to provide an alternative to the liquid form commonly used in phage therapy. This lyophilized (freeze-dried/stabilized) product represents a technological breakthrough, offering increased flexibility, stability and application versatility. This innovative development is in direct response to Cytophage working with the poultry industry on phage products with the goal to reduce the use of broad-spectrum antibiotics and replace them with targeted phages.

Product highlights:

• Ready to use; dissolves easily in water to simplify the process for the farmer;
• Dose controlled; can simply be added to the specified water levels;
• Temperature stable; does not require a cold chain -- making it easily usable in hotter climates such as Southeast Asia;
• Lightweight packaging; easily portable to the barn.

Cytophage chief executive officer Dr. Steven Theriault, commented: "The importance of eliminating the need for a cold chain cannot be overstated. Offering phages in lyophilized form represents a competitive advantage over other phage producers who have only liquid products that require refrigeration. Our innovative manufacturing increases our products' heat tolerance and shelf life."

Cytophage anticipates leveraging this innovation globally across all existing and pending product lines. The company believes it is currently the only phage company worldwide capable of delivering a lyophilized phage product at scale without significantly increasing costs for consumers.

About Cytophage Technologies Ltd.

Cytophage Technologies is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.